Client Result
Smart Communications Platform Ooma Acquires 2600Hz, Inc.
2 minute read | October.24.2023
2 minute read | October.24.2023
1 minute read | January.09.2023
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
March.09.2022
Orrick advises Twist Bioscience on upsized public offering of common stock.
June.18.2021
We are advising disruptive AgTech company Local Bounti on its definitive agreement to become publicly traded via a SPAC merger with Leo Holdings.
June.25.2020
June.08.2020
Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its $107.4 million follow-on offering.
May.13.2020
May.07.2020
March.04.2020
August.27.2019
August.05.2019